Last reviewed · How we verify
flucloxacillin
At a glance
| Generic name | flucloxacillin |
|---|---|
| Also known as | Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol |
| Sponsor | Karlstad University |
| Target | Matrix metalloproteinase-9, Androgen receptor, Penicillin-binding protein 1A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Antibiotic Concentrations Among Critically Ill Patients
- BonE and Joint Infections - Simplifying Treatment in Children Trial (PHASE4)
- Staphylococcus Aureus Network Adaptive Platform Trial (PHASE4)
- ElastoMeric Infusion Pumps for Hospital AntibioTICs (NA)
- Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (PHASE3)
- The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring
- Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |